Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2024 | Anxiety | Research

The Prader-Willi syndrome Profile: validation of a new measure of behavioral and emotional problems in Prader-Willi syndrome

Authors: Elisabeth M. Dykens, Elizabeth Roof, Hailee Hunt-Hawkins

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Abstract

Background

Prader-Willi syndrome (PWS) is a rare, neurodevelopmental disorder caused by the lack of expression of paternally imprinted genes on chromosome 15q11-13. PWS features a complex behavioral phenotype, including hyperphagia, anxiety, compulsivity, rigidity, repetitive speech, temper outbursts, aggressivity, and skin-picking. Questionnaires exist for measuring hyperphagia, but not for the aggregation of other problems that are distinctive to PWS. A PWS-specific tool is needed for phenotypic research, and to help evaluate treatment efficacy in future clinical trials aimed at attenuating PWS’s hyperphagia and related problems. In this 4-phase study, we leveraged our expertise in PWS with feedback from families and specialists to validate the PWS Profile, a novel, informant-based measure of behavioral and emotional problems in this syndrome.

Results

The authors developed a bank of 73 items that tapped both common and less frequent but clinically significant problems in PWS (Phase 1). An iterative feedback process with families and stakeholders was used to ensure content and construct validity (Phase 2). After adding, omitting, or revising items, in Phase 3, we pilot tested the measure in 112 participants. Results were reviewed by an international team of PWS specialists and revised again (Phase 3). The final, 57-item Profile was then administered to 761 participants (Phase 4). Principal component factor analyses (n = 873) revealed eight conceptually meaningful factors, accounting for 60.52% of test variance, and were readily interpretated as: Rigidity, Insistence; Aggressive Behaviors; Repetitive Questioning, Speech; Compulsive Behaviors; Depression, Anxiety; Hoarding; Negative Distorted Thinking; and Magical Distorted Thinking. Factors were internally consistent and showed good test-retest reliability and convergent validity with existent measures of behavioral problems. Profile factors were not related to IQ, BMI, or parental SES. Three Profile factors differed across PWS genetic subtypes. Age and gender differences were found in only one Profile factor, Hoarding.

Conclusions

The PWS Profile is a valid, psychometrically-sound questionnaire that already has shown responsivity to treatment in a previous clinical trial. The Profile can extend the reach of future clinical trials by evaluating the impact of novel agents not only on hyperphagia, but also on the emotional and behavioral problems that characterize PWS.

Available only for authorised users

Butler MG, Hartin SN, Hossain WA, Manzardo AM, Kimonis V, Dykens E. Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study. J Med Genet. 2019;56:149–53.PubMedCrossRef

Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14(1):10–26.PubMedCrossRef

Holland A, Whittington J, Hinton E. The paradox of Prader-Willi syndrome: a genetic model of starvation. Lancet. 2003;362:989–91.PubMedCrossRef

Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obes. 2007;15:1816–26.CrossRef

Fehnel SE, Brown TM, Nelson L, Chen A, Kim DD, Roof E, Dykens EM. Development of the hyperphagia questionnaire for use in prader-Willi syndrome clinical trials. Value Health. 2015;18:A25.CrossRef

Roof E, Deal CL, McCandles SE, Cowan RL, Miller JL, Hamilton JK, et al. Intranasal carbetocin reduces hyperphagia, anxiousness and distress in Prader-Willi syndrome: CARE-PWS phase 3 trial. J Clin Endocrinol Metab. 2023;00:1–13. https://doi.org/10.1210/clinem/dgad015.CrossRef

Dykens EM, Miller J, Angulo M, Roof E, Reidy M, Hatoum HT, et al. Reduction of hyperphagia in children and youth with prader-Willi syndrome: results of a multicenter, randomized, double blind, placebo-controlled study assessing safety and efficacy of intranasal carbetocin. J Clin Invest. 2018;3(12):e98333.

Kayadjanin N, Schwartz L, Farrar E, Comtois KA, Strong TV. High levels of caregiver burden in Prader-Willi syndrome. PLoS ONE. 2018;13(3):e0194655. https://doi.org/10.1371/journal.pone.0194655.CrossRef

Schwartz L, Caixàs A, Dimitropoulos A, Dykens E, Duis J, Einfeld S, et al. Behavioral features in Prader-Willi syndrome: Consensus paper from the International PWS Clinical Trial Consortium. J Neurodev Disord. 2021;13:25. https://doi.org/10.1186/s11689-021-09373-2.CrossRefPubMedPubMedCentral

10.

Milner KM, Craig EE, Thompson RJ, Veltman MWM, Thomas NS, Roberts S, et al. Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatr. 2005;46:1089–96.CrossRef

11.

Dykens EM, Roof E. Behavior in Prader-Willi syndrome: relationship to genetic subtypes and age. J Child Psychol Psychiatr. 2008;49:1001–8.CrossRef

12.

Dykens EM, Roof E, Hunt-Hawkins H, Danker N, Lee EB, Shivers CM, et al. Diagnoses and characteristics of autism spectrum disorders in children with prader-Willi syndrome. J Neurodev Disord. 2017;9:1–12.CrossRef

13.

Dimitropoulos A, Ho A, Feldman B. Social responsiveness, and competence in Prader-Willi syndrome: direct comparison to autism spectrum disorder. J Autism Dev Disord. 2012;43:103–13.CrossRef

14.

Yang L, Zhan G-d, Ding J-j, Wang H-J, Ma D, Huang G-y et al. Psychiatric illness and intellectual disability in the Prader–Willi syndrome with different molecular defects - a meta-analysis. 2013; PloS One: 8(8), e72640.

15.

Chevalere J, Postal V, Jauregui J, Copet O, Laurier V, Thuilleaux C. (2015). Executive functions and Prader-Willi syndrome: Global deficit linked with intellectual level and syndrome-specific associations. Am J Intellect Dev Disabil. 2015;120: 215–229.

16.

Woodcock KA, Oliver C, Humphreys GW. Task-switching deficits and repetitive behaviour in genetic neurodevelopmental disorders: data from children with prader–Willi syndrome chromosome 15 q11– q13 deletion and boys with Fragile X syndrome. Cogn Neuropsychol. 2009;26:172–94.PubMedCrossRef

17.

Dykens EM, Roof E, Hunt-Hawkins H, Daniell C, Jurgensmeyer S. Profiles and trajectories of impaired social cognition in people with prader-Willi syndrome. PLoS ONE. 2019;14:e0223162. https://doi.org/10.1371/journal.pone.0223162.CrossRefPubMedPubMedCentral

18.

Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KEP, Schrander-Stumpel CTRM, et al. Psychiatric illness in a cohort of adults with prader–Willi syndrome. Res Dev Disabil. 2011;32:1729–35.PubMedCrossRef

19.

Whittington J, Holland A. A review of psychiatric conceptions of mental and behavioural disorders in Prader-Willi syndrome. Neurosci Biobehav Rev. 2018;95:396–405.PubMedCrossRef

20.

Dykens EM. Psychiatric disorders in people with intellectual disabilities: steps toward eliminating research and clinical care disparities. In: Hodapp RM, Fidler J, editors. Int Rev Res Dev Disabil. Amsterdam: Academic Press; 2016. pp. 277–302.

21.

American Psychiatric Association. Diagnostic and statistical Manual of Mental Disorders-5-TR. Washington DC: American Psychiatric Association; 2022.CrossRef

22.

International Classification of Diseases., Eleventh Revision (ICD-11). World Health Organization (WHO) 2019/2021 https://icd.who.int/browse11.

23.

Fletcher RJ, Barnhill J, Cooper SA. Diagnostic manual-intellectual Disability-2: a Textbook of Mental disorders in persons with intellectual disability. Kingston, NY: National Association for Dual Diagnosis Press; 2016.

24.

Dykens EM, Roof E, Hunt-Hawkins H. The cure for us is a lot of things’: how young people with prader-Willi syndrome view themselves and future clinical trials. J Appl Res Intellect Disabil. 2021;1–11. https://doi.org/10.1111/jar.12950JARID.

25.

Cotter SP, Schwartz L, Strong TV, Bender RH, Fehnel SE. The Prader-Willi syndrome anxiousness and distress behaviors questionnaire: development and psychometric validation. Value Health. 2023;26(2):243–50. https://doi.org/10.1016/j.jval.2022.08.004.CrossRefPubMed

26.

Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms & profiles: an integrated system of multi-informant assessment. Burlington VT: University of Vermont; 2001.

27.

Goodman R. Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry. 2001;40:1337–45.PubMedCrossRef

28.

Mohr C, Tonge BJ, Einfeld SL. The development of a new measure for the assessment of psychopathology in adults with intellectual disability. J Intellect Disabil Res. 2005;49(7):469–810.PubMedCrossRef

29.

Aman MG, Singh NN. Aberrant behavior checklist: community, residential Manual. Slosson Educational Publications; 2017.

30.

Raspa M, Bann CM, Gwaltney A, Benke TA, Fu C, Glaze DG, et al. A psychometric evaluation of the motor-behavioral assessment scale for use as an outcome measure in Rett syndrome clinical trials. Am J Intellect Dev Disabil. 2022;125(6):493–509.CrossRef

31.

Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42:1377–92.PubMedPubMedCentralCrossRef

32.

Mervis CB, Robinson BF, Bertrand J, Morris CA, Klein–Tasman BP, Armstrong SC. The Williams syndrome cognitive profile. Brain Cogn. 2000;44:604–28.PubMedCrossRef

33.

Edgin JO, Mason GM, Allman MJ, Capone GT, DeLeon I, Maslen C, et al. Development and validation of the Arizona cognitive test battery for Down syndrome. J Neurodevelop Disord. 2010;2:149–64.CrossRef

34.

Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. Diazoxide choline extended-release tablet in people with prader-Willi syndrome: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2023;00:1–10. https://doi.org/10.1210/clinem/dgad014.CrossRef

35.

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research., U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research. & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4(79). https://doi.org/10.1186/1477-7525-4-79.

36.

Cronbach L, Meehl PE. Construct validity in psychological tests. Psychol Bull. 1955;52:281–302.PubMedCrossRef

37.

Dimitropoulos A, Blackford J, Walden T, Thompson T. Compulsive behavior in Prader–Willi syndrome: examining severity in early childhood. Res Dev Disabil. 2006;27:190–202.PubMedCrossRef

38.

Hardestya DM, Bearden WO. The use of expert judges in scale development implications for improving face validity of measures of unobservable constructs. J Bus Res. 2004;57:98–107.

39.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.PubMedCrossRef

40.

Bodfish JW, Symons FJ, Parker DE, Lewis MH. Repetitive behavior scale–revised (RBS-R). APA PsycTests. 2000. https://doi.org/10.1037/t17338-000.CrossRef

41.

Sparrow SS, Cicchetti DV, Saulnier CA. Vineland adaptive behavior Scales-III. Minneapolis, MN: Pearson Publishers; 2016.

42.

Kaufman AS, Kaufman NL. Kaufman brief intelligence Test-2. Minneapolis: MN; Pearson; 2004.

43.

Jacoby J, Matell MS. Three-point likert scales are good enough. J Mark Res. 1991;8:495–500.CrossRef

44.

Bohonowych J, Miller J, McCandless S, Strong T. The global prader-Willi syndrome registry: development, launch, and early demographics. Genes (Basel). 2019;10(9):713.PubMedCrossRef

45.

Costello AB, Osborne J. Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. Practical Assess Res Evaluation. 2005;10(7). https://doi.org/10.7275/jyj1-4868.

46.

Knekta E, Runyon C, Eddy S. One size doesn’t fit all: using factor analysis to gather validity evidence when using surveys in your research. CBE Life Sci Educ. 2019;18:1–17.CrossRef

47.

Kieffer KM. An introductory primer on the appropriate use of exploratory and confirmatory factor analysis. Res Sch. 1911;6(2):75–92.

48.

Tavakol M, Dennick R. Making sense of Cronbach’s alpha. Int J Med Educ. 2011;2:53–5.PubMedPubMedCentralCrossRef

49.

Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155–63.PubMedPubMedCentralCrossRef

50.

Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for affective disorders and Schizophrenia for school-age children-present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980–8.PubMedCrossRef

51.

Miles J, Shevlin M. Applying regression and correlation: a guide for students and researchers. London: Sage; 2001.

52.

Feurer ID, Dimitropoulos A, Stone WL, Roof E, Butler MG, Thompson T. The latent variable structure of the compulsive behavior checklist in people with prader-Willi syndrome. J Intellect Disabil Res. 1998;42:472–80.PubMedPubMedCentralCrossRef

53.

Streiner D. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess. 2003;80:99–103.PubMedCrossRef

54.

Harries J, Guscia R, Nettelbeck T, Kirby N. Impact of additional disabilities on adaptive behavior and support profiles for people with intellectual disabilities. Am J Intellect Dev Disabil. 2009;114(4):237–53.PubMedCrossRef

55.

Shelkowitz E, Gantz MG, Ridenour TA, Scheimann AO, Strong T, Bohonowych J, et al. Neuropsychiatric features of prader–Willi syndrome. Am J Med Genet. 2002;188A:1457–63.

56.

Symons FJ, Butler MG, Sanders MD, Feurer ID, Thompson T. Self-injurious behavior and prader-Willi syndrome: behavioral forms and body locations. Am J Ment Retard. 1999;104(3):260–9.PubMedPubMedCentralCrossRef

57.

Greaves N, Prince E, Evans DW, Charman T. Repetitive and ritualistic behaviour in children with prader–Willi syndrome and children with autism. J Intellect Disabil Res. 2006;50:92–100.PubMedCrossRef

58.

Moss J, Oliver C, Arron K, Burbidge C, Berg K. The prevalence and phenomenology of repetitive behavior in genetic syndromes. J Autism Dev Disord. 2009;39:572–88.PubMedCrossRef

59.

Clarke DJ, Boer H, Whittington J, Holland A, Butler J, Webb T. Prader-Willi syndrome, compulsive and ritualistic behaviors: the first population-based survey. Br J Psychiatry. 2002;180:358–62. 5.PubMedCrossRef

60.

Dykens EM, Leckman JF. Obsessions and compulsions in Prader-Willi syndrome. J Child Psychol Psychiat. 1996;37:995–1002.PubMedCrossRef

61.

Dykens EM, Roof E. Cleaning up hoarding disorder: the case of Prader-Willi syndrome. Am J Psychiat, under review.

62.

Samuels JF, Bienvenu OPJ, Grados MA, Cullen B, Riddle MA, Liang K-y, et al. Prevalence and correlates of hoarding behavior in a community-based sample. Behav Res Ther. 2008;46:836–44.PubMedPubMedCentralCrossRef

63.

MagiatiI I, Ozsivadjian A, Kerns CM. Phenomenology, and presentation of anxiety in Autism Spectrum Disorder. In: Jerns CM, Renno P, Storch EA, Kendall PC, Wood JJ, editors. Anxiety in children and adolescents with Autism Spectrum Disorder. Cambridge; Elsevier; 2017. pp. 33–54.

64.

Lozano R, Thompson T, Dixon-Weber J, Erickson CA, Berry-Kravis E, Williams S, et al. Observable symptoms of anxiety in individuals with fragile X syndrome: parent and caregiver perspectives. Genes. 2022;13:1660. https://doi.org/10.3390/genes13091660.CrossRefPubMedPubMedCentral

65.

Tsai J-H, Scheimann AO, McCandless SE, Strong TV, Bridges JFP. Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best–worst scaling. J Med Econ. 2018;21(12):1230–7.PubMedCrossRef

Title: The Prader-Willi syndrome Profile: validation of a new measure of behavioral and emotional problems in Prader-Willi syndrome
Authors: Elisabeth M. Dykens
Elizabeth Roof
Hailee Hunt-Hawkins
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Anxiety
Published in: Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-024-03045-9

2024 ASCO Annual Meeting

Springer Medicine

The Prader-Willi syndrome Profile: validation of a new measure of behavioral and emotional problems in Prader-Willi syndrome

Abstract

Background

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan

The impact of amplification on quality of life in women with Turner syndrome

Economic burden of patients with post-surgical chronic and transient hypoparathyroidism in the United States examined using insurance claims data

Neuropsychological profile associated with KAT6A syndrome: Emergent genotype-phenotype trends

Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database

Cronkhite‒Canada syndrome as inflammatory hamartomatous polyposis: new evidence from whole transcriptome sequencing of colonic polyps